SCHEMBL56332

SCHEMBL56332

O=[N+]([O-])c1cnccc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.49
HTT P42858 3/20 0.47
LMNA P02545 3/20 0.47
MAPK1 P28482 2/20 0.47
RAB9A P51151 1/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
TDP1 Q9NUW8 2/20 0.46
KDM4E B2RXH2 1/20 0.46
MAPT P10636 4/20 0.46
POLB P06746 1/20 0.46
CHUK O15111 1/20 0.45
TSHR P16473 1/20 0.44
VCAM1 P19320 2/20 0.43
GAA P10253 1/20 0.43
HSP90AA1 P07900 1/20 0.43
PDE4B Q07343 1/20 0.42
PDE4D Q08499 1/20 0.42
PDE7A Q13946 1/20 0.42
PDE7B Q9NP56 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30258234 1.00 ALDH1A1 (0.49) ALDH1A1HTTLMNAMAPK1RAB9A
SCHEMBL7920586 1.00 ALDH1A1 (0.49) ALDH1A1HTTLMNAMAPK1RAB9A
Hydrochloric Acid SCHEMBL1137081 0.98 ALDH1A1 (0.47) ALDH1A1HTTLMNAMAPK1RAB9A
Pyrimidine SCHEMBL27956767 0.93 ALDH1A1 (0.47) ALDH1A1HTTLMNAMAPK1RAB9A
SCHEMBL827098 0.83 MAPK1 (0.48) ALDH1A1HTTLMNAMAPK1RAB9A
SCHEMBL8568179 0.80 ALDH1A1 (0.53) ALDH1A1HTTLMNAMAPK1RAB9A
Ethylene SCHEMBL27749127 0.77 ALDH1A1 (0.50) ALDH1A1HTTLMNAMAPK1RAB9A
SCHEMBL619318 0.76 MAPT (0.52) ALDH1A1HTTLMNAMAPK1MEN1
SCHEMBL6973083 0.76 MAPT (0.56) ALDH1A1HTTLMNAMAPK1MEN1
SCHEMBL10734254 0.75 ALDH1A1 (0.49) ALDH1A1HTTLMNAMAPK1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1858 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118721925-A Electronic polycrystalline silicon multifunctional inner packaging material and preparation method thereof 四川固朔新材料有限公司 2024-10-01 CN claimed
CN-117586250-A Preparation method of human respiratory syncytial virus inhibitor intermediate 潍坊汇韬化工有限公司 2024-02-23 CN claimed
CN-115322190-B Pyridoimidazole acyl sulfonamide derivative, and preparation method and application thereof 山东大学 2023-09-22 CN claimed
WO-2023143034-A1 PYRIDOIMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 山东大学 2023-08-03 WO claimed
CN-116351100-A System and method for extracting nitro reaction product by supercritical carbon dioxide 天津凯莱英医药科技发展有限公司 2023-06-30 CN claimed
CN-115322190-A Pyridoimidazole acylsulfonamide derivative and preparation method and application thereof 山东大学 2022-11-11 CN claimed
CN-113956268-B 6-bromo-1-chlorobenzothiophene [2,3-c ] pyridine and synthetic method 西安欧得光电材料有限公司 2022-07-15 CN claimed
CN-114478522-A Pyridoimidazole derivative and preparation method and application thereof 山东大学 2022-05-13 CN claimed
CN-113956268-A 6-bromo-1-chlorobenzothiophene [2,3-c ] pyridine and synthetic method 西安欧得光电材料有限公司 2022-01-21 CN claimed
CN-112707860-A Synthesis method of active intermediate 4-chloro-3-nitropyridine 南京波普生物医药研发有限公司 2021-04-27 CN claimed
CN-100439367-C Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon AVENTIS PHARMA INC (US) 2008-12-03 CN claimed
US-20080200496-A1 SUBSTITUTED 1H-PYRROLO[3,2-b, 3,2-c, and 2,3-c]PYRIDINE-2-CARBOXAMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE Ie AVENTIS PHARMACEUTICALS INC. (US) 2008-08-21 US claimed
CN-101245066-A Method for producing 7-alkoxyl-2, 9-diazafluorene UNIV FUDAN (CN) 2008-08-20 CN claimed
US-7348326-B2 Heteroaryl fused aminoalkyl imidazole derivatives: selective modulators of GABAa receptors NEUROGEN CORPORATION (US) 2008-03-25 US claimed
EP-1747220-A1 SUBSTITUTED 1H-PYRROLO 3,2-B, 3,2-C, AND 2,3-C¨PYRIDINE-2-CARBOXAMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I EPSILON Aventis Pharmaceuticals Inc. (US) 2007-01-31 EP claimed
CN-1906194-A Substituted 1H-pyrrolo [3, 2-b, 3, 2-c and 2, 3-c ] pyridine-2-carboxamides and related analogs as inhibitors of casein kinase ie AVENTIS PHARMA INC (US) 2007-01-31 CN claimed
WO-2005061498-A1 SUBSTITUTED 1H-PYRROLO[3,2-B, 3,2-C, AND 2,3-C]PYRIDINE-2-CARBOXAMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I EPSILON AVENTIS PHARMACEUTICALS INC. (US) 2005-07-07 WO claimed
US-20050131012-A1 Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon AVENTIS PHARMACEUTICALS INC. (US) 2005-06-16 US claimed
EP-0088023-B1 PYRIDO(3',4':4,5)FURO(3,2-G) COUMARINES OR PYRIDO(3,4-H)PSORALENES, PREPARATION, USE IN COSMETOLOGY AND AS MEDICAMENTS AND COMPOSITIONS CONTAINING THEM INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 1987-01-14 EP claimed
US-4266060-A ANTITUMOR ANTIVIRAL AGENTS FOR TREATMENT OF CANCER AGENCE NATIONALE DE VAL ORISATION DE LA RECHERCHE (ANVAR) (FR) 1981-05-05 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200496-A1 SUBSTITUTED 1H-PYRROLO[3,2-b, 3,2-c, and 2,3-c]PYRIDINE-2-CARBOXAMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE Ie CSNK1E, CSNK1G3, CSNK2A3 ALDH1A1 3613/4885HTT 3995/4885LMNA 589/4885
US-20050131012-A1 Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon CSNK2A3, PACSIN2, CSNK1G3 ALDH1A1 4044/4885HTT 3317/4885LMNA 342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.